Abstract
Probucol is a lipid-lowering drug that has an antioxidant effect. The authors sought to investigate the effect of probucol on stent restenosis after the usual 3-day pretreatment protocol. From March 1999 to August 2000, 78 patients (mean age, 56 +/- 8; 49 male) with coronary artery disease who underwent coronary stenting were enrolled. After a diagnostic angiography was done, each eligible patient was randomized to either the probucol or the control group. Following the procedure, ticlopidine was administered for 1 month; aspirin and probucol continuously. Angiographic follow-up was done in 81% (57/70) and angiographic restenosis was not different between the two groups (21% vs. 24%; P = 0.81). In conclusion, antioxidant probucol did not show a beneficial effect on stent restenosis with 3 days of premedication protocol.
Copyright 2002 Wiley-Liss, Inc.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antioxidants / administration & dosage
-
Antioxidants / therapeutic use*
-
Aspirin / administration & dosage
-
Aspirin / therapeutic use
-
Blood Vessel Prosthesis Implantation / adverse effects*
-
Coronary Angiography
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / surgery*
-
Drug Therapy, Combination
-
Female
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use
-
Follow-Up Studies
-
Graft Occlusion, Vascular / diagnostic imaging
-
Graft Occlusion, Vascular / etiology*
-
Graft Occlusion, Vascular / prevention & control*
-
Humans
-
Male
-
Middle Aged
-
Postoperative Complications*
-
Probucol / administration & dosage
-
Probucol / therapeutic use*
-
Stents / adverse effects*
-
Ticlopidine / administration & dosage
-
Ticlopidine / therapeutic use
-
Time Factors
Substances
-
Antioxidants
-
Fibrinolytic Agents
-
Ticlopidine
-
Probucol
-
Aspirin